Primary ocular herpes is usually seen as a follicular conjunctivitis and blepharitis, with or without involvement of the cornea. It is unknown, however, to what extent asymptomatic and/or subclinical primary disease occurs, and whether primary ocular herpes follows direct droplet spread to the eye.
Previous models of murine ocular herpes have used trauma (scarification) to introduce virus into the cornea, producing disease which results in significant corneal scarring. To mimic a likely route of infection in humans, a droplet containing virus was placed on the mouse eye and clinical disease recorded. At least 1 month after inoculation, serum was assayed for neutralising antibodies and the cornea, iris, and trigeminal ganglion were investigated for evidence of herpes simplex virus type 1, by cocultivation and the polymerase chain reaction. Some animals showed a severe ulcerative blepharitis with little to no involvement of the cornea, while disease was undetectable in others. The development of disease depended on the dose and strain of virus and age of the animal, with older mice appearing more resistant. Virus was isolated from the trigeminal ganglion ofyounger animals inoculated with higher doses of virus, after 21 days in culture, suggesting that latency had been established. Neutralising antibodies were present in most mice irrespective of the presence -of recognisable clinical disease. Using primers for the thymidine kinase and glycoprotein C regions of the viral genome, herpes simplex virus type 1 DNA was found in the cornea, iris, and trigeminal ganglion of most animals and showed a good correlation with the presence of neutralising antibodies. It would thus appear that herpes simplex virus type 1 is able to accede into the cornea, iris, and trigeminal ganglion following nontraumatic application of virus onto the mouse eye. This model mimics primary ocular disease in humans and may be useful for studies on recurrent disease and the spread of ocular herpes.
Herpes simplex virus type 1 (HSV-1) is an important cause of ocular disease in both developed and underdeveloped countries.'2 At present, despite advances in elucidating the molecular biology of HSV-1, 3 we are still unable to prevent infection and the subsequent recurrences which may occur in the eye. The mechanism by which virus gains access to the cornea and trigeminal ganglion (TG) to infect and to establish a latent infection is central to the pathogenesis of herpes keratitis (HSK), its prevention, treatment, and eventual eradication.
The frequent occurrence of asymptomatic salivary shedding of HSV-1,456 provides indirect evidence of asymptomatic primary oral disease and for implicating the mouth as the main site for the acquisition and spread of HSV-1 within the community. The proportion of cases of primary herpetic eye disease that are asymptomatic however, is not known and they may play an important role in the development of recurrent corneal disease. The sensitive polymerase chain reaction (PCR), has been used to detect HSV-1 DNA in the corneas of patients with previous HSK,789 in the absence of an isolation of cocultivation."' HSV-1 DNA has also been detected in non-herpetic corneal diseases such as aphakic bullous keratopathy, keratoconus, and interstitial keratitis,7" 1 a finding consistent with the occurrence of asymptomatic HSV-1 ocular infection.
Primary ocular infection in the mouse has been well studied"-'4 using corneal trauma for the inoculation of virus. Although non-invasive inoculation has been used in rabbits' there has been only one previous murine study in which disease was reported.'2 The clinical findings, however, were not described nor were the ocular tissues and TG tested for the isolation of virus.
After scarification the disease which occurs is predominantly corneal, and usually results in extensive scarring. In humans, however, there is no evidence that such corneal trauma is necessary for ocular infection or the establishment of latency. In lid ulceration, central corneal geographic ulceration, and varying degrees of mydriasis. By the end of the third week there was lid scarring with hair loss and the corneas were vascularised and scarred.
The right eyes remained normal throughout the study.
Experiment 2
Topically infected mice (groups E with strain McKrae and G with strain SC16) developed disease in the inoculated eye in the following manner: mild lid oedema and a squamous blepharitis was present by day 3 (10/15 in group E and 13/15 in group G), with two mice in Group G showed lid vesicles. By the end of the first week mice had developed varying degrees of the upper an lower lid ulcerative blepharitis (6/15 in group E and 9/15 in group G). In addition, four of these mice (one from group E and three from group G had a mild punctate epithelial keratopathy. One mouse (group G) developed an encephalitis by day 10 and was killed. At 2 weeks there were varying degrees of lid scarring and hair loss (Fig 1) and (Tables 1 and  2 ). Of these 13 mice, viral DNA was detected using all three primers as follows: (a) in the cornea, iris, and TG of five mice (Al, A2, A4, AS, A 13), (b) in two of the tissues in four mice (A9, A14, A15, and A16), and (c) in one of the tissues in three mice (A3, A6, and A 12). Both the TK1 and TK2, but not the gC amplification products were present in the iris and TG of A3, and only in the iris of A9. Conversely, the gC but not the TK amplification products were present in the TG of two animals (A6 and A15). These may represent genomic retention of false positives. Furthermore Scarification with virus. HSV-1 DNA was detected (using all three primers) in all tissues of each mouse in group C, with the exception of the iris and cornea of one animal (C2), where it could be detected using the TK2 and gC primers but not with the TK1 primers ( Table 2) .
Controls. There were no detectable amplification products using the three primers in the cornea, iris, or TG of eight control mice, apart from the presence of the TK amplification products in the TG of B 1 (Table 1) .
PRODUCT DIGESTION AND HYBRIDISATION
The amplification products (Fig 3a) were cleaved as predicted by the relevant restriction enzymes, confirming their identities (Fig 3b and c) . Similarly, the TKI and TK2 amplification products from positive samples hybridised to the internal oligonucleotide probe, whereas the negative control samples did not (Fig 3d) . ISOLATION spreading across the cornea which was associated with mild iris hyperaemia. By day 3, the corneas ofall control and 19/24 infected mice had re-epithelialised. Five of the 24 infected mice had persistent central oval epithelial defects and focal areas of lid excoriation. At 1 week, all the central epithelial defects had healed, two mice being left with scarred vascularised corneas.
Discussion HSV-1 infection is usually acquired by direct or indirect contact spread from an infected individual. The non-traumatic acquisition of HSV-1 by direct droplet spread to the eye, however, has not been fully investigated. Asymptomatic ocular infection'78 has been postulated to occur based on the finding of anti-HSV-1 antibodies in the tear film of seronegative individuals23 and although reports are contradictory, the isolation of HSV-1 in the tear film of persons with no prior history of herpes.624 Lower doses of HSV-1 strain McKrae did not produce disease after topical inoculation of older mice. Primary ocular disease did occur, however, following topical inoculation with either strain of HSV-1 (SC16 or McKrae), when higher doses were used in younger mice. This probably reflects the combination of increasing the dose of virus and the greater susceptibility of younger mice." The incidence and severity of disease was slightly greater when SC16 was used for inoculation. For both strains of virus the disease was predominantly confined to the lids and resembled that which occurs in human primary ocular herpetic blepharitis.I7 18 The pattern of disease (lid and corneal ulceration) in mice scarified with HSV-1 was similar to that reported previously. '2 1426 Topical application of HSV-1, induced the production of neutralising antibody in 83% of animals in expt 1 and in all animals in expt 2, irrespective of recognisable clinical disease. Mice which developed clinical disease, however, had significantly higher levels of antibody than those which did not. The level of antibody produced was highest in younger mice which had been scarified with HSV-1 strain McKrae 
